<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39613712</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>164</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>Effect of pentoxifylline on hepcidin and iron profile in hemodialysis patients: A randomized, double-blind, placebo-controlled clinical trial.</ArticleTitle><Pagination><StartPage>263</StartPage><EndPage>270</EndPage><MedlinePgn>263-270</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2024.09.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(24)00654-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hemodialysis (HD) patients often have elevated levels of hepcidin hormone, which is a key regulator of systemic iron homeostasis. While pentoxifylline (PTX) has been demonstrated to have anti-inflammatory properties, it is unclear if these effects would also have an inhibitory effect on hepcidin. This study aimed to examine the potential role of PTX on hepcidin and its consequent effects on iron profile and anemia in HD patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighty HD patients were randomly assigned 1:1 to the pentoxifylline group, receiving a daily dose of PTX (800mg), or the placebo group, receiving placebo capsules for 6-months. Different laboratory parameters, including hepcidin, hemoglobin (Hb), red blood cells (RBCs), hypoxia-inducible factor-2 alpha (HIF-2&#x3b1;), serum iron, total iron-binding capacity (TIBC), ferritin, transferrin saturation (TSAT), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs.CRP), were used for evaluation the patients' response.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the PTX-treated patients, the hepcidin levels reduced significantly (p=0.001) from 628.03 (334.4-800.85)ng/ml to 235.25 (192.8-508.76)ng/ml, and this reduction was also statistically significant as compared to the placebo group (p&lt;0.001). Also, there were significant changes (p&lt;0.001) regarding other iron hemostasis parameters including Hb, RBCs, serum iron, TIBC, TSAT, and HIF-2&#x3b1;. Levels of IL-6 and hs.CRP, as a reflection of inflammatory status, decreased significantly (p=0.002 and p=0.003, respectively) in the pentoxifylline group, and the percent reduction in these parameters was also statistically significant compared to the placebo group (p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study reveals that PTX reduces hepcidin levels and consequently provides an improvement in the iron profile and anemia in HD patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zakaria</LastName><ForeName>Hadeer</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Electronic address: gs-hadeer.elsayed@alexu.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamdy</LastName><ForeName>Noha Alaa</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayed-Ahmed</LastName><ForeName>Nagy A H</ForeName><Initials>NAH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Mallah</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064451">Hepcidins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SD6QCT3TSU</RegistryNumber><NameOfSubstance UI="D010431">Pentoxifylline</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064451" MajorTopicYN="Y">Hepcidins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010431" MajorTopicYN="Y">Pentoxifylline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="Y">Iron</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="Y">Anemia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anemia</Keyword><Keyword MajorTopicYN="N">Hemodialysis</Keyword><Keyword MajorTopicYN="N">Hemodi&#xe1;lisis</Keyword><Keyword MajorTopicYN="N">Hepcidin</Keyword><Keyword MajorTopicYN="N">Hepcidina</Keyword><Keyword MajorTopicYN="N">Iron metabolism</Keyword><Keyword MajorTopicYN="N">Metabolismo del hierro</Keyword><Keyword MajorTopicYN="N">Pentoxifilina</Keyword><Keyword MajorTopicYN="N">Pentoxifylline</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>23</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>22</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39613712</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2024.09.032</ArticleId><ArticleId IdType="pii">S0025-7753(24)00654-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39236980</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2254-8874</ISSN><JournalIssue CitedMedium="Internet"><Volume>224</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Revista clinica espanola</Title><ISOAbbreviation>Rev Clin Esp (Barc)</ISOAbbreviation></Journal><ArticleTitle>Anemia of inflammation and iron metabolism in chronic diseases.</ArticleTitle><Pagination><StartPage>598</StartPage><EndPage>608</EndPage><MedlinePgn>598-608</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rceng.2024.09.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2254-8874(24)00116-4</ELocationID><Abstract><AbstractText>Anemia of Inflammation begins with the activation of the immune system and the subsequent release of cytokines that lead to an elevation of hepcidin, responsible for hypoferremia, and a suppression of erythropoiesis due to lack of iron. The anemia is usually mild/moderate, normocytic/normochromic and is the most prevalent, after iron deficiency anemia, and is the most common in patients with chronic diseases, in the elderly and in hospitalized patients. Anemia can influence the patient's quality of life and have a negative impact on survival. Treatment should be aimed at improving the underlying disease and correcting the anemia. Intravenous iron, erythropoietin and prolyl hydroxylase inhibitors are the current basis of treatment, but future therapy is directed against hepcidin, which is ultimately responsible for anemia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Espa&#xf1;a, S.L.U. and Sociedad Espa&#xf1;ola de Medicina Interna (SEMI). All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conde D&#xed;ez</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicina de Familia, Servicio C&#xe1;ntabro de Salud, Centro de Salud Camargo Costa, Malia&#xf1;o, Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Las Cuevas Allende</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medicina de Familia, Servicio C&#xe1;ntabro de Salud, Centro de Salud Altamira, Puente de San Miguel, Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conde Garc&#xed;a</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hemat&#xf3;logo jubilado [jefe del Servicio de Hematolog&#xed;a del Hospital Marqu&#xe9;s de Valdecilla, Santander. Catedr&#xe1;tico de Medicina de la Universidad de Cantabria], Santander, Spain. Electronic address: condeeulogio@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Clin Esp (Barc)</MedlineTA><NlmUniqueID>101632437</NlmUniqueID><ISSNLinking>2254-8874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064451">Hepcidins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="Y">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="Y">Anemia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064451" MajorTopicYN="N">Hepcidins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018798" MajorTopicYN="N">Anemia, Iron-Deficiency</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anemia</Keyword><Keyword MajorTopicYN="N">Chronic diseases</Keyword><Keyword MajorTopicYN="N">Enfermedades cr&#xf3;nicas</Keyword><Keyword MajorTopicYN="N">Hepcidin</Keyword><Keyword MajorTopicYN="N">Hepcidina</Keyword><Keyword MajorTopicYN="N">Inflamaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Iron metabolism</Keyword><Keyword MajorTopicYN="N">Metabolismo hierro</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>5</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39236980</ArticleId><ArticleId IdType="doi">10.1016/j.rceng.2024.09.002</ArticleId><ArticleId IdType="pii">S2254-8874(24)00116-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33358297</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>156</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>12</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>Anaemia of chronic diseases: Pathophysiology, diagnosis and treatment.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>242</EndPage><MedlinePgn>235-242</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2020.07.035</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(20)30653-9</ELocationID><Abstract><AbstractText>Anaemia of chronic disease (ACD) is generated by the activation of the immune system by autoantigens, microbial molecules or tumour antigens resulting in the release of cytokines that cause an elevation of serum hepcidin, hypoferraemia, suppression of erythropoiesis, decrease in erythropoietin (EPO) and shortening of the half-life of red blood cells. Anaemia is usually normocytic and normochromic, which is the most prevalent after iron deficiency anaemia, and it is the most frequent in the elderly and in hospitalized patients. If the anaemia is severe, the patient's quality of life deteriorates, and it can have a negative impact on survival. Treatment is aimed at controlling the underlying disease and correcting anaemia. Sometimes intravenous iron and EPO have been used, but the therapeutic future is directed against hepcidin, which is the final target of anaemia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Las Cuevas Allende</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio C&#xe1;ntabro de Salud. Centro de Salud El Alisal, Santander, Cantabria, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az de Entresotos</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio C&#xe1;ntabro de Salud, Santander, Cantabria, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conde D&#xed;ez</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio C&#xe1;ntabro de Salud. Centro de Salud Altamira, Cantabria, Espa&#xf1;a. Electronic address: sue_santander@yahoo.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Anemia de las enfermedades cr&#xf3;nicas: fisiopatolog&#xed;a, diagn&#xf3;stico y tratamiento.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064451">Hepcidins</NameOfSubstance></Chemical><Chemical><RegistryNumber>11096-26-7</RegistryNumber><NameOfSubstance UI="D004921">Erythropoietin</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="Y">Anemia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004921" MajorTopicYN="Y">Erythropoietin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064451" MajorTopicYN="N">Hepcidins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antagonistas hepcidina</Keyword><Keyword MajorTopicYN="N">Ferroportin</Keyword><Keyword MajorTopicYN="N">Ferroportina</Keyword><Keyword MajorTopicYN="N">Hepcidin</Keyword><Keyword MajorTopicYN="N">Hepcidin antagonists</Keyword><Keyword MajorTopicYN="N">Hepcidina</Keyword><Keyword MajorTopicYN="N">Interleucina-6</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Iron metabolism</Keyword><Keyword MajorTopicYN="N">Metabolismo hierro</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>28</Day><Hour>10</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33358297</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2020.07.035</ArticleId><ArticleId IdType="pii">S0025-7753(20)30653-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28073521</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>Current status of iron metabolism: Clinical and therapeutic implications.</ArticleTitle><Pagination><StartPage>218</StartPage><EndPage>224</EndPage><MedlinePgn>218-224</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2016.10.047</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(16)30664-9</ELocationID><Abstract><AbstractText>Hepcidin is the main regulator of iron metabolism and a pathogenic factor in iron disorders. Hepcidin deficiency causes iron overload, whereas hepcidin excess causes or contributes to the development of iron-restricted anaemia in chronic inflammatory diseases. We know the mechanisms involved in the synthesis of hepcidin and, under physiological conditions, there is a balance between activating signals and inhibitory signals that regulate its synthesis. The former include those related to plasmatic iron level and also those related to chronic inflammatory diseases. The most important inhibitory signals are related to active erythropoiesis and to matriptase-2. Knowing how hepcidin is synthesised has helped design new pharmacological treatments whose main target is the hepcidin. In the near future, there will be effective treatments aimed at correcting the defect of many of these iron metabolism disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conde Diez</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicina de Familia, Servicio C&#xe1;ntabro de Salud, Santander (Cantabria), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Las Cuevas Allende</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medicina de Familia, Servicio C&#xe1;ntabro de Salud, Centro de Salud Bajo As&#xf3;n, Ampuero (Cantabria), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conde Garc&#xed;a</LastName><ForeName>Eulogio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Hematolog&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, Universidad de Cantabria, Santander (Cantabria), Espa&#xf1;a. Electronic address: euconde@humv.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Estado actual del metabolismo del hierro: implicaciones cl&#xed;nicas y terap&#xe9;uticas.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064451">Hepcidins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000098742">Ferroportin</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027682" MajorTopicYN="N">Cation Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064451" MajorTopicYN="N">Hepcidins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019189" MajorTopicYN="N">Iron Metabolism Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000098742" MajorTopicYN="N">Ferroportin</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Agonistas de la hepcidina</Keyword><Keyword MajorTopicYN="N">Antagonistas de la hepcidina</Keyword><Keyword MajorTopicYN="N">Ferroportin</Keyword><Keyword MajorTopicYN="N">Ferroportina</Keyword><Keyword MajorTopicYN="N">Hepcidin</Keyword><Keyword MajorTopicYN="N">Hepcidin agonists</Keyword><Keyword MajorTopicYN="N">Hepcidin antagonists</Keyword><Keyword MajorTopicYN="N">Hepcidina</Keyword><Keyword MajorTopicYN="N">Iron metabolism</Keyword><Keyword MajorTopicYN="N">Metabolismo del hierro</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28073521</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2016.10.047</ArticleId><ArticleId IdType="pii">S0025-7753(16)30664-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27737394</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2175-8239</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Jornal brasileiro de nefrologia</Title><ISOAbbreviation>J Bras Nefrol</ISOAbbreviation></Journal><ArticleTitle>Hepcidin: an important iron metabolism regulator in chronic kidney disease.</ArticleTitle><Pagination><StartPage>351</StartPage><EndPage>355</EndPage><MedlinePgn>351-355</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5935/0101-2800.20160053</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0101-28002016000300351</ELocationID><Abstract><AbstractText>Anemia is a common complication and its impact on morbimortality in patients with chronic kidney disease (CKD) is well known. The discovery of hepcidin and its functions has contributed to a better understanding of iron metabolism disorders in CKD anemia. Hepcidin is a peptide mainly produced by hepatocytes and, through a connection with ferroportin, it regulates iron absorption in the duodenum and its release of stock cells. High hepcidin concentrations described in patients with CKD, especially in more advanced stages are attributed to decreased renal excretion and increased production. The elevation of hepcidin has been associated with infection, inflammation, atherosclerosis, insulin resistance and oxidative stress. Some strategies were tested to reduce the effects of hepcidin in patients with CKD, however more studies are necessary to assess the impact of its modulation in the management of anemia in this population. Resumo Anemia &#xe9; uma complica&#xe7;&#xe3;o frequente e seu impacto na morbimortalidade &#xe9; bem conhecido em pacientes com doen&#xe7;a renal cr&#xf4;nica (DRC). A descoberta da hepcidina e de suas fun&#xe7;&#xf5;es contribu&#xed;ram para melhor compreens&#xe3;o dos dist&#xfa;rbios do metabolismo de ferro na anemia da DRC. Hepcidina &#xe9; um pept&#xed;deo produzido principalmente pelos hepat&#xf3;citos, e atrav&#xe9;s de sua liga&#xe7;&#xe3;o com a ferroportina, regula a absor&#xe7;&#xe3;o de ferro no duodeno e sua libera&#xe7;&#xe3;o das c&#xe9;lulas de estoque. Altas concentra&#xe7;&#xf5;es de hepcidina descritas em pacientes com DRC, principalmente em est&#xe1;dios mais avan&#xe7;ados, s&#xe3;o atribu&#xed;das &#xe0; diminui&#xe7;&#xe3;o da excre&#xe7;&#xe3;o renal e ao aumento de sua produ&#xe7;&#xe3;o. Eleva&#xe7;&#xe3;o de hepcidina tem sido associada &#xe0; ocorr&#xea;ncia de infec&#xe7;&#xe3;o, inflama&#xe7;&#xe3;o, aterosclerose, resist&#xea;ncia &#xe0; insulina e estresse oxidativo. Algumas estrat&#xe9;gias foram testadas para diminuir os efeitos da hepcidina em pacientes com DRC, entretanto, ser&#xe3;o necess&#xe1;rios mais estudos para avaliar o impacto de sua modula&#xe7;&#xe3;o no manejo da anemia nessa popula&#xe7;&#xe3;o.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antunes</LastName><ForeName>Sandra Azevedo</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Hospital Universit&#xe1;rio da Universidade Federal de Alagoas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canziani</LastName><ForeName>Maria Eug&#xea;nia Fernandes</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Universidade Federal de S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>J Bras Nefrol</MedlineTA><NlmUniqueID>9426946</NlmUniqueID><ISSNLinking>0101-2800</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064451">Hepcidins</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064451" MajorTopicYN="N">Hepcidins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27737394</ArticleId><ArticleId IdType="doi">10.5935/0101-2800.20160053</ArticleId><ArticleId IdType="pii">S0101-28002016000300351</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25433101</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1699-5198</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Nutricion hospitalaria</Title><ISOAbbreviation>Nutr Hosp</ISOAbbreviation></Journal><ArticleTitle>[Effect of hepcidin on iron metabolism in athletes].</ArticleTitle><Pagination><StartPage>1218</StartPage><EndPage>1231</EndPage><MedlinePgn>1218-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3305/nh.2014.30.6.7440</ELocationID><Abstract><AbstractText>The role of iron in the human body is essential, and athletes must always try to keep an adequate iron status. Hepcidin is proposed as the main hormone responsible for the control of iron reserves in the body, given its ability to induce degradation of ferroportin. The action of hepcidin on ferroportin leads to a decreased dietary iron absorption, as well as to a decrease in macrophages. Several factors such as the iron status, the amount of dietary iron, the inflammation, the hypoxia, the testosterone and the physical exercise have been pointed out as affecting the synthesis of hepcidin. This study has aimed at analysing the researches on hepcidin response to exercise, as well as designing a specific strategy to prevent a potential ferropenic status in athletes. The main findings are an association between exercise at an intensity over 65% VO2max and transient increases in the synthesis of hepcidin, and a possible regulatory effect of intermittent hypoxic stimuli in the early post-exercise recovery. Other factors such as the training volume, sex, kind of exercise or the type of surface where the training takes place do not seem to affect the response of hepcidin to exercise.</AbstractText><CopyrightInformation>Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dom&#xed;nguez</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Ciencias de la Actividad F&#xed;sica y el Deporte, Universidad Alfonso X El Sabio. Madrid.. rdomiher@uax.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garnacho-Casta&#xf1;o</LastName><ForeName>Manuel Vicente</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Departamento de Fisiolog&#xed;a e Inmunolog&#xed;a, Universidad de Barcelona. Espa&#xf1;a.. mavigarcas@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mat&#xe9;-Mu&#xf1;oz</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departamento de Ciencias de la Actividad F&#xed;sica y el Deporte, Universidad Alfonso X El Sabio. Madrid.. jmatmuo@uax.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Efecto de la hepcidina en el metabolismo del hierro en deportistas.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nutr Hosp</MedlineTA><NlmUniqueID>9100365</NlmUniqueID><ISSNLinking>0212-1611</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064451">Hepcidins</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000693" MajorTopicYN="N">Anaerobiosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000747" MajorTopicYN="N">Anemia, Hypochromic</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056352" MajorTopicYN="Y">Athletes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064451" MajorTopicYN="N">Hepcidins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090463" MajorTopicYN="N">Iron Deficiencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Las funciones del hierro en el organismo son esenciales, siendo uno de los objetivos del deportista mantener un estado f&#xe9;rrico adecuado. La hepcidina, se ha propuesto como la principal hormona responsable de controlar las reservas corporales de hierro, a trav&#xe9;s de su capacidad para degradar la ferroportina. La acci&#xf3;n de la hepcidina sobre la ferroportina provoca una disminuci&#xf3;n de la absorci&#xf3;n del hierro proveniente de la dieta, as&#xed; como de los macr&#xf3;fagos. Distintos factores como el estado f&#xe9;rrico del individuo, la cantidad de hierro proveniente de la dieta, la inflamaci&#xf3;n, hipoxia, testosterona y el ejercicio, se han comprobado que afectan a la capacidad de s&#xed;ntesis de hepcidina. Los objetivos del presente trabajo han sido analizar las investigaciones que actualmente han estudiado la respuesta de la hepcidina al ejercicio, as&#xed; como el dise&#xf1;o de un plan espec&#xed;fico que tenga por objeto prevenir posibles estados ferrop&#xe9;nicos en el deportista. Los principales hallazgos han sido una asociaci&#xf3;n entre el ejercicio a una intensidad superior al 65% VO2m&#xe1;x con incrementos transitorios en la s&#xed;ntesis de hepcidina, as&#xed; como un posible efecto regulador de los est&#xed;mulos de hipoxia intermitente en la recuperaci&#xf3;n temprana postejercicio. Otros factores como el volumen de entrenamiento, sexo, modalidad de ejercicio o el tipo de superficie sobre la que se practica el ejercicio no parecen afectar a la respuesta de la hepcidina al ejercicio.</AbstractText><CopyrightInformation>Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25433101</ArticleId><ArticleId IdType="doi">10.3305/nh.2014.30.6.7440</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>